- Report
- October 2024
- 188 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- May 2024
- 150 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- March 2025
- 194 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- January 2025
- 124 Pages
Global
From €2851EUR$2,999USD£2,395GBP
- Report
- July 2024
- 150 Pages
Global
From €3565EUR$3,750USD£2,995GBP
- Report
- May 2024
- 140 Pages
Global
From €4705EUR$4,949USD£3,952GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- January 2025
Global
From €2804EUR$2,950USD£2,356GBP
- Report
- September 2024
- 89 Pages
Global
From €4421EUR$4,650USD£3,714GBP
- Report
- September 2024
- 210 Pages
Global
From €2282EUR$2,400USD£1,917GBP
- Report
- August 2024
- 195 Pages
Global
From €2282EUR$2,400USD£1,917GBP
- Report
- June 2024
- 250 Pages
Global
From €2282EUR$2,400USD£1,917GBP
- Report
- May 2024
- 100 Pages
Global
From €2282EUR$2,400USD£1,917GBP
- Report
- May 2024
- 420 Pages
Global
From €2852EUR$3,000USD£2,396GBP
- Report
- October 2024
- 181 Pages
Global
From €2210EUR$2,325USD£1,857GBP
€4421EUR$4,650USD£3,714GBP
- Report
- July 2024
- 335 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- October 2024
- 192 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 196 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 198 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- March 2025
- 198 Pages
Global
From €5324EUR$5,600USD£4,472GBP

Immune Checkpoint Inhibitor drugs are a type of immunotherapy used to treat immune disorders. They work by blocking proteins that act as “checkpoints” in the immune system, allowing the body to recognize and attack cancer cells. These drugs are used to treat a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. They are also used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease.
Immune Checkpoint Inhibitor drugs are a relatively new form of treatment, and the market is still in its early stages. However, the potential of these drugs has led to a surge in research and development, with many companies investing in the development of new drugs.
Some of the major companies in the Immune Checkpoint Inhibitor market include Bristol-Myers Squibb, Merck, AstraZeneca, Roche, and Novartis. Other companies such as Pfizer, AbbVie, and Johnson & Johnson are also involved in the development of these drugs. Show Less Read more